日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cyclin Y interacts with Chk1 to activate RRM2/STAT3 signaling and promotes radioresistance in non-small cell lung cancer.

细胞周期蛋白 Y 与 Chk1 相互作用,激活 RRM2/STAT3 信号通路,促进非小细胞肺癌的放射抗性

Liu Zhiwei, Xue Huichan, Wang Zhi, Zhao Ye, Xu Shuangbing, Dong Xiaorong

Retraction Note: β-Trcp and CK1δ-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma

撤稿声明:β-Trcp 和 CK1δ 介导的 LZTS2 降解激活 PI3K/AKT 信号通路,从而驱动肝细胞癌的肿瘤发生和转移。

Lu, Yanwei; Li, Xudong; Liu, Hongli; Xue, Jun; Zeng, Zhen; Dong, Xiaorong; Zhang, Tao; Wu, Gang; Yang, Kunyu; Xu, Shuangbing

[Ensartinib Combined with Radiotherapy for the Treatment of Advanced Primary Pulmonary Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring 
TPM3-ALK Fusion: A Case Report]

[恩沙替尼联合放射疗法治疗携带TPM3-ALK融合基因的晚期原发性肺上皮样炎性肌纤维母细胞肉瘤:病例报告]

Zhao, Ye; Xu, Shuangbing

Correction: CDP138 silencing inhibits TGF-β/Smad signaling to impair radioresistance and metastasis via GDF15 in lung cancer

更正:CDP138 沉默通过抑制 TGF-β/Smad 信号通路,进而通过 GDF15 削弱肺癌的放射抗性和转移能力。

Lu, Yanwei; Ma, Jia; Li, Yan; Huang, Jing; Zhang, Sheng; Yin, Zhongyuan; Ren, Jinghua; Huang, Kai; Wu, Gang; Yang, Kunyu; Xu, Shuangbing

Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma

EGFR突变型III-pN2期肺腺癌辅助TKI治疗与TKI联合化疗的疗效比较

Li, Qiwen; Ma, Li; Qiu, Bo; Wen, Yuzhi; Liang, Wenhua; Hu, Wanming; Chen, Naibin; Zhang, Tian; Xu, Shuangbing; Chen, Lingjuan; Guo, Minzhang; Zhao, Yi; Liu, Songran; Guo, Jinyu; Wang, Junye; Wang, Siyu; Wang, Xin; Pang, Qingsong; Long, Hao; Liu, Hui

CDP138 silencing inhibits TGF-β/Smad signaling to impair radioresistance and metastasis via GDF15 in lung cancer

CDP138沉默通过抑制TGF-β/Smad信号通路,进而通过GDF15削弱肺癌的放射抗性和转移能力。

Lu, Yanwei; Ma, Jia; Li, Yan; Huang, Jing; Zhang, Sheng; Yin, Zhongyuan; Ren, Jinghua; Huang, Kai; Wu, Gang; Yang, Kunyu; Xu, Shuangbing